The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Andrew J. Armstrong

ScM, Divisions of Medical Oncology and Urology

Departments of Medicine and Surgery

Duke Cancer Institute

[email]@duke.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • ScM, Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke Cancer Institute. 2012
  • DUMC Box 102002, Durham, NC 27710. 2011
  • Duke Prostate Center, Durham, USA. 2010
  • Division of Medical Oncology, Department of Medicine, DUMC, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, USA. 2007 - 2010
  • Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, USA. 2010
  • Duke Comprehensive Cancer Center, Duke University, Durham, NC 27705, USA. 2007 - 2009
  • Department of Medicine and Surgery, Duke Comprehensive Cancer Center, Durham, NC 27710, USA. 2009
  • Duke Prostate Center, 2424 Erwin Road, Durham, NC 27705, USA. 2008

References

  1. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of Mammalian target of rapamycin. Armstrong, A.J., George, D.J., Halabi, S. J. Clin. Oncol. (2012) [Pubmed]
  2. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Armstrong, A.J., Marengo, M.S., Oltean, S., Kemeny, G., Bitting, R.L., Turnbull, J.D., Herold, C.I., Marcom, P.K., George, D.J., Garcia-Blanco, M.A. Mol. Cancer Res. (2011) [Pubmed]
  3. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong, A.J., George, D.J. Prostate Cancer Prostatic Dis. (2010) [Pubmed]
  4. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Armstrong, A.J., Tannock, I.F., de Wit, R., George, D.J., Eisenberger, M., Halabi, S. Eur. J. Cancer (2010) [Pubmed]
  5. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Armstrong, A.J., Netto, G.J., Rudek, M.A., Halabi, S., Wood, D.P., Creel, P.A., Mundy, K., Davis, S.L., Wang, T., Albadine, R., Schultz, L., Partin, A.W., Jimeno, A., Fedor, H., Febbo, P.G., George, D.J., Gurganus, R., De Marzo, A.M., Carducci, M.A. Clin. Cancer Res. (2010) [Pubmed]
  6. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Armstrong, A.J., Garrett-Mayer, E., de Wit, R., Tannock, I., Eisenberger, M. Clin. Cancer Res. (2010) [Pubmed]
  7. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Armstrong, A.J., Halabi, S., de Wit, R., Tannock, I.F., Eisenberger, M. Prostate Cancer Prostatic Dis. (2009) [Pubmed]
  8. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Armstrong, A.J., Febbo, P.G. Oncologist (2009) [Pubmed]
  9. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Armstrong, A.J., Creel, P., Turnbull, J., Moore, C., Jaffe, T.A., Haley, S., Petros, W., Yenser, S., Gockerman, J.P., Sleep, D., Hurwitz, H., George, D.J. Clin. Cancer Res. (2008) [Pubmed]
  10. New drug development in metastatic prostate cancer. Armstrong, A.J., George, D.J. Urol. Oncol. (2008) [Pubmed]
  11. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Armstrong, A.J., Garrett-Mayer, E.S., Yang, Y.C., de Wit, R., Tannock, I.F., Eisenberger, M. Clin. Cancer Res. (2007) [Pubmed]
  12. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Armstrong, A.J., Garrett-Mayer, E., Ou Yang, Y.C., Carducci, M.A., Tannock, I., de Wit, R., Eisenberger, M. J. Clin. Oncol. (2007) [Pubmed]
  13. Systemic strategies for prostate cancer. Armstrong, A.J., Febbo, P.G., George, D.J., Moul, J. Minerva. Urol. Nefrol (2007) [Pubmed]
 
WikiGenes - Universities